Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

  • Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19
  • MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage
  • Switzerland based Molecular Partners, a global leader in the development of DARPin …
/by

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

  • Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD):
    • Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183 million (+50% cc) and Promacta/Revolade USD 442 million (+16% cc)
    • Sandoz …
/by

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

  • Q3 net sales from continuing operations1were in line with prior year (cc2, +1% USD):
    • Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183 million (+50% cc) and Promacta/Revolade USD 442 million (+16% cc)
    • Sandoz …
/by

Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

  • C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 
  • Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the complement system’s alternative pathway, targeting the underlying cause of C3G.4–6
  • Data presented at the American Society of Nephrology (ASN) 2020 Annual Meeting shows that investigational iptacopan …
/by

Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)

  • Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseases
  • IgA nephropathy (IgAN), while rare, is the most common form of glomerulonephritis, affecting mostly young adults with no approved treatment option and significant risk to progress to e …
/by

Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)

  • Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and death

  • There are no approved disease modifying therapies that delay disease onset or slow progression of the disease

  • Branaplam (LMI070) is an orally administered, small molecule RNA splicing modulator that could potentially reduce the levels of mutant huntingtin protein

Basel, October …

/by

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

  • If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1
  • Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2, and 80% of high-risk patients do not reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets despite the widespread …
/by

Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)

  • The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3 glomerulopathy (C3G). 
  • PRIME is granted for medicines that may offer major therapeutic advance or benefit patients without treatment options.
  • C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1 …
/by

World Sight Day 2020

2.2 billion people are blind or visually impaired worldwide. Half of them lack access to eye care. Together, we are working to change that. This World Sight Day, Novartis is proud to partner with the International Agency for the Prevention of Blindness (IAPB) to expand equitable access to eye care in remote communities with the initiation of early detection eye health screening programs.

…
/by